Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

Rhea-AI Summary

Sensei Biotherapeutics, Inc. (SNSE) to participate in fireside chat at Canaccord Genuity’s 43rd Annual Growth Conference, offering webcast of presentation and replay for 90 days.

BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a fireside chat at Canaccord Genuity’s 43^rd Annual Growth Conference, being held in Boston, MA, on Wednesday, August 9, 2023 at 9:30 a.m. ET.

A webcast of Sensei’s presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the webcast is available here.

About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39.  For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn. 

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

FAQ

What is the latest announcement from Sensei Biotherapeutics, Inc. (SNSE)?

Sensei Biotherapeutics, Inc. (SNSE) will participate in a fireside chat at Canaccord Genuity’s 43rd Annual Growth Conference in Boston, MA, with a webcast of the presentation available in the Investors section of the Sensei website and a replay accessible for approximately 90 days following the event.

Where can I find the webcast of Sensei Biotherapeutics, Inc. (SNSE) presentation?

The webcast of Sensei Biotherapeutics, Inc. (SNSE) presentation will be available in the Investors section of the Sensei website.

When will the webcast replay of Sensei Biotherapeutics, Inc. (SNSE) presentation be available?

The webcast replay of Sensei Biotherapeutics, Inc. (SNSE) presentation will be available on the website for approximately 90 days following the event.